Shots:

• Santhera to provide its lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program and validates hNE as a target and shed light on lonodelestat as a potential therapy against COVID-19
• Researchers at CSHL are part of the consortium of international non/clinical experts called the ‘NETwork to target neutrophils in COVID-19’. The NETwork will evaluate the role of neutrophils and NETs in the pathology of COVID-19 and hNE along with other targets to treat COVID-19
• Lonodelestat (POL6014) is a selective hNE inhibitor and has completed its P-I single-dose escalation studies in healthy volunteers and patients with CF and is currently investigated in a multiple ascending dose study in CF patients

Click here ­to­ read full press release/ article | Ref: Santhera | Image: Medgazette